The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

Agrawal, R. K., Aird, E. G. A., Barrett, J. M., Barrett-Lee, Peter, Bentzen, S. M., Bliss, J. M., Brown, J., Dewar, J. A., Dobbs, H. J., Haviland, J. S., Hoskin, P. J., Hopwood, P., Lawton, P. A., Magee, B. J., Mills, J., Morgan, D. A. L., Owen, J. R., Simmons, S., Sumo, G., Sydenham, M. A., Venables, K. and Yarnold, J. R. 2008. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. The Lancet 371 (9618) , pp. 1098-1107. 10.1016/S0140-6736(08)60348-7

Full text not available from this repository.

Abstract

Background. The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2·0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefi ts of radiotherapy schedules using fraction sizes larger than 2·0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy. Methods. Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2·0 Gy over 5 weeks or 40 Gy in 15 fractions of 2·67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specifi ed principal endpoints were local-regional tumour relapse, defi ned as reappearance of cancer at irradiated sites, late normal tissue eff ects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. Findings. 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6·0 years (IQR 5·0–6·2) the rate of local-regional tumour relapse at 5 years was 2·2% (95% CI 1·3–3·1) in the 40 Gy group and 3·3% (95% CI 2·2 to 4·5) in the 50 Gy group, representing an absolute diff erence of –0·7% (95% CI –1·7% to 0·9%)—ie, the absolute diff erence in local-regional relapse could be up to 1·7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse eff ects after 40 Gy than after 50 Gy. Interpretation. A radiation schedule delivering 40 Gy in 15 fractions seems to off er rates of local-regional tumour relapse and late adverse eff ects at least as favourable as the standard schedule of 50 Gy in 25 fractions.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Publisher:	Elsevier
ISSN:	0140-6736
Last Modified:	10 Oct 2017 14:10
URI:	https://orca.cardiff.ac.uk/id/eprint/25707

Citation Data

Cited 879 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item